Abstract

Chromatography remains the workhorse in antibody purification; however process development and characterisation still require significant resources. The high number of operating parameters involved requires extensive experimentation, traditionally performed at small- and pilot-scale, leading to demands in terms of materials and time that can be a challenge. The main objective of this research was the establishment of a novel High Throughput Process Development (HTPD) workflow combining scale-down chromatography experimentation with advanced decision-support techniques in order to minimise the consumption of resources and accelerate the development timeframe. Additionally, the HTPD workflow provides a framework to rapidly manipulate large datasets in an automated fashion. The central component of the HTPD workflow is the systematic integration of a microscale chromatography experimentation strategy with an advanced chromatogram evaluation method, design of experiments (DoE) and multivariate data analysis. The outputs of this are leveraged into the screening and optimisation components of the workflow. For the screening component, a decision-support tool was developed combining different multi-criteria decision-making techniques to enable a fair comparison of a number of CEX resin candidates and determine those that demonstrate superior purification performance. This provided a rational methodology for screening chromatography resins and process parameters. For the optimisation component, the workflow leverages insights provided through screening experimentation to guide subsequent DoE experiments so as to tune significant process parameters for the selected resin. The resulting empirical correlations are linked to a stochastic modelling technique so as to predict the optimal and most robust chromatographic process parameters to achieve the desired performance criteria.

Highlights

  • The development of a chromatographic purification process in biopharmaceutical manufacturing is highly challenging and complex especially at early stages

  • The previous section described the individual components of the High Throughput Process Development (HTPD) workflow and highlighted its capability to adapt to different user specifications

  • A case-study was formulated in collaboration with MedImmune to demonstrate the HTPD workflow, using a bispecific monoclonal antibody with high aggregate concentration post Protein A chromatography

Read more

Summary

Introduction

The development of a chromatographic purification process in biopharmaceutical manufacturing is highly challenging and complex especially at early stages. The large number of parameters that could potentially have a significant impact on the chromatographic separation performance requires extensive experimentation traditionally performed at bench-scale in order to optimise the operating conditions. Extensive experimentation requires a substantial amount of clarified material and long timelines [1]. High-throughput experimentation (HTE) has emerged as a powerful technique to accelerate process development with relatively small amounts of feedstock material. HTE has highlighted the impetus for high-throughput analytics and the development of data manipulation and analysis tools to cope with the large datasets and leverage sufficiently the resulting information [2]. The overall aim of this paper is the establishment of a rational and systematic high-throughput process development workflow for the purification of therapeutic antibodies that incorporates decision-support techniques to leverage high-throughput purification data

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.